|
 India will make bedaquiline, one of just two new TB drugs marketed
over the last 50 years, available at 140 government-run TB treatment
centers by November, said Sunil Kharpade, head of India's Central TB
Division. The drug is currently available at only six centers.
"We've conducted training in several states in the last few months,
and we're prepared to start giving it to patients across 140
centers," Kharpade told Reuters.
Health experts and activists welcomed the move, but said the
government must do even more against TB, which claims the lives of
thousands of Indians each year.
"India's TB program has made a lot of progress in the last few
years," said Jennifer Furin, an infectious diseases expert at
Harvard Medical School.
"But compared to what they need to do if they are serious about
eliminating TB in eight short years, they have barely scratched the
surface."
India has nearly a quarter of the world's TB cases, and poor
infection control practices and a stressed public healthcare system
make it a hotbed for spreading the drug-resistant bacteria.
India has provided bedaquiline to only 300 patients, with another
300 courses available. There are plans to get treatment for 1,000
more patients in the next year, said Kharpade.
But that is way short of India's requirements with nearly 2.8
million new TB cases a year, and 80,000 patients with multi-drug
resistant (MDR) TB. About a third of those with MDR TB are eligible
to use bedaquiline, according to the World Health Organization,
leaving thousands of Indians without access.
[to top of second column] |
"What that means is those people continue to transmit the bacteria
to the community and it makes elimination impossible," Furin said.
Kharpade says the country has been cautious in rolling out the drug
to ensure people don't develop resistance to it. But some health
experts believe the response has been too slow.
Groups like Lawyers Collective and Medecins Sans Frontieres have
called for expanded access to bedaquiline as well as delamanid,
another drug for late-stage TB patients marketed by Japan's Otsuka
Holdings Co Ltd.
"We got these drugs after half a century of stagnant research," said
Mario Raviglione, head of the WHO's TB-control program.
"We don't want to lose these drugs for future people in need."
(Reporting by Zeba Siddiqui; Editing by Randy Fabi)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
